OCULAR THERAPEUTIX, INC Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
OCULAR THERAPEUTIX, INC (OCUL) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 5.77 million shares for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2026-02-05
- OCULAR THERAPEUTIX, INC incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2023-09-30 was 5.77M shares.
- OCULAR THERAPEUTIX, INC incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2022-06-30 was 5.77M shares, a 0.00% change year-over-year.
- OCULAR THERAPEUTIX, INC incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2022-03-31 was 5.77M shares, a 0.00% change year-over-year.
- OCULAR THERAPEUTIX, INC incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2021-09-30 was 5.77M shares, a 0.00% change year-over-year.
- OCULAR THERAPEUTIX, INC incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2023 was 5.77M shares, a 0.00% change from fiscal 2022.
- OCULAR THERAPEUTIX, INC incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2022 was 5.77M shares, a 0.00% change from fiscal 2021.
- OCULAR THERAPEUTIX, INC incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2021 was 5.77M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|
| 2023-12-31 | 5.77M shares 10-K · filed 2026-02-05 | |||
| 2023-09-30 | 5.77M shares 10-Q · filed 2024-11-14 | 5.77M shares 10-Q · filed 2024-11-14 | ||
| 2022-12-31 | 5.77M shares 10-K · filed 2025-03-03 | |||
| 2022-09-30 | 5.77M shares 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | 5.77M shares 10-Q · filed 2023-08-07 | 5.77M shares 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | 5.77M shares 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | 5.77M shares 10-K · filed 2024-03-11 | |||
| 2021-09-30 | 5.77M shares 10-Q · filed 2022-11-07 | 5.77M shares 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | 5.77M shares 10-Q · filed 2022-08-08 | 5.77M shares 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | 5.77M shares 10-Q · filed 2022-05-09 | |||
| 2020-09-30 | 5.77M shares 10-Q · filed 2021-11-08 | |||
| 2019-09-30 | 5.77M shares 10-Q · filed 2020-11-05 | |||
| 2019-03-31 | 1.92M shares 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |